Genomic Health Inc.’s (GHDX) lead product is Oncotype DX, which is used for early stage breast cancer patients to predict the likelihood of cancer recurrence.
Even though sales of Oncotype remain robust and the company remains optimistic about its prospects, we are highly concerned about the company’s reliance on the product for growth. We believe that Genomic needs to expand its product portfolio in order to sustain growth.
Furthermore, we are also concerned about the company’s weak pipeline. These concerns have caused us to downgrade the stock to Underperform.Zacks Investment Research
